Adjuvant Chemotherapy for HR-Positive, ERBB2 -Negative Breast CancerAdjuvant Chemotherapy for HR-Positive, ERBB2 -Negative Breast Cancer
This cohort study examines changes from 2010 to 2022 in use of adjuvant chemotherapy for early-stage hormone receptor–positive, ERBB2-negative breast cancer by age, genomic risk, and nodal involvement.
FDA approves Wegovy weight loss pill from Novo NordiskFDA approves Wegovy weight loss pill from Novo Nordisk
The Food and Drug Administration on Monday approved a pill version of Wegovy, Novo Nordisk’s blockbuster weight loss drug. The Food and Drug Administration on Monday approved a pill version of Wegovy, Novo Nordisk’s blockbuster weight loss drug.
FDA approves pill version of Novo Nordisk’s Wegovy, possibly widening accessFDA approves pill version of Novo Nordisk’s Wegovy, possibly widening access
The Food and Drug Administration on Monday approved the oral version of Novo Nordisk’s injectable weight loss drug Wegovy, making it the first GLP-1 pill to be cleared by regulators for obesity and possibly allowing many more Americans to access a highly effective treatment. The Wegovy pill, whose approval for weight loss was widely anticipated, Read More
GLP-1s don’t always work for weight loss. Researchers are trying to figure out whyGLP-1s don’t always work for weight loss. Researchers are trying to figure out why
GLP-1 weight loss drugs have transformed obesity treatment, but not everyone loses lots of weight. Researchers say figuring out why is the key to the future of this treatment method. GLP-1 weight loss drugs have transformed obesity treatment, but not everyone loses lots of weight. Researchers say figuring out why is the key to Read More
Adding Tucatinib in First-Line Maintenance Boosts PFS in HER2-Positive Breast CancerAdding Tucatinib in First-Line Maintenance Boosts PFS in HER2-Positive Breast Cancer
(MedPage Today) — At the San Antonio Breast Cancer Symposium, investigators presented results from HER2CLIMB-05, a registrational trial evaluating the addition of tucatinib (Tukysa) to trastuzumab (Herceptin) and pertuzumab (Perjeta) maintenance…
Next-Gen Oral SERD Cuts Recurrence Risk in Early Breast CancerNext-Gen Oral SERD Cuts Recurrence Risk in Early Breast Cancer
(MedPage Today) — At the San Antonio Breast Cancer Symposium, investigators reported phase III results showing that the oral selective estrogen-receptor degrader (SERD) giredestrant significantly reduced recurrence risk compared with standard…
High-fat diets make liver cells more susceptible to cancer-causing mutations, study showsHigh-fat diets make liver cells more susceptible to cancer-causing mutations, study shows
One of the biggest risk factors for developing liver cancer is a high-fat diet. A new study from MIT reveals how a fatty diet rewires liver cells and makes them more prone to becoming cancerous.
The throughline between Ozempic and ProzacThe throughline between Ozempic and Prozac
Good morning! I hope everyone has a week of many cookies and few emails ahead. You’ll hear from me once more this year, tomorrow. How safe is food in the U.S.? In any given year in the U.S., contaminated food causes around 48 million illnesses and 3,000 deaths. And food experts predict that the Trump Read More
GLP-1s don’t always work for weight loss. Researchers are trying to figure out whyGLP-1s don’t always work for weight loss. Researchers are trying to figure out why
GLP-1 weight loss drugs have transformed obesity treatment, but not everyone loses lots of weight. Researchers say figuring out why is the key to the future of this treatment method. GLP-1 weight loss drugs have transformed obesity treatment, but not everyone loses lots of weight. Researchers say figuring out why is the key to Read More
Opinion: STAT+: What Ozempic might tell us about the future of Alzheimer’sOpinion: STAT+: What Ozempic might tell us about the future of Alzheimer’s
In the weeks leading up to Dec. 3, I imagined a fantastic headline: “Ozempic treats Alzheimer’s disease.” On that day, at the CtAD 2025 meeting (CtAD stands for Clinical Trials in Alzheimer’s Disease), in the Sapphire Ballroom of the Hilton San Diego Bayfront hotel, Novo Nordisk would present to the assembly of scientists and biopharma Read More